Form 144 Filer Information

FORM 144

144: Filer Information

144: Securities Information

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

Filer CIK	0001555851		
Filer CCC	xxxxxxx		
Is this a LIVE or TEST Filing?	● LIVE ○ TEST		
Submission Contact Information			
Name			
Phone			
E-Mail Address			
144: Issuer Information			
Name of Issuer	Adaptimmune Therapeutics PLC		
SEC File Number	001-37368		
Address of Issuer	60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE UNITED KINGDOM OX14 4RX		
Phone	44 1235 430000		
Name of Person for Whose Account the Securities are To Be Sold	Rawcliffe Adrian		
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.			
Relationship to Issuer	Chief Executive Officer		
144: Securities Information			
Title of the Class of Securities To Be Sold	American Depositary Shares		
Name and Address of the Broker	MAXIM GROUP 300 Park Ave 16th Floor New York NEW YORK NY 10022		
Number of Shares or Other Units To Be Sold	30473		
Aggregate Market Value	17917.00		
Number of Shares or Other Units Outstanding	255880000		
Approximate Date of Sale	01/13/2025		
Name the Securities Exchange	NASDAQ		

Title of the Class of Securities To Be Sold	American Depositary Shares
Name and Address of the Broker	MAXIM GROUP 300 Park Ave 16th Floor New York New York NY 10022
Number of Shares or Other Units To Be Sold	29096
Aggregate Market Value	16724.00
Number of Shares or Other Units Outstanding	255880000
Approximate Date of Sale	01/15/2025
Name the Securities Exchange	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Till till Oliver		
Title of the Class	American Depositary Shares	
Data you Acquired	01/13/2025	
Date you Acquired	01/13/2023	
Nature of Acquisition Transaction	Sell to cover exercise (cashless)	
Name of Person from Whom Acquired	Adaptimmune Therapeutics plc	
Is this a Gift?	Date Donor Acquired	
Amount of Securities Acquired	30473	
Date of Payment	01/13/2025	
Nature of Decreeout	COMPENSATION	
Nature of Payment	COMPENSATION	

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

## 144: Securities To Be Sold

Title of the Class	American Depositary Shares
Date you Acquired	01/15/2025
Nature of Acquisition Transaction	Sell to cover exercise (cashless)
Name of Person from Whom Acquired	Adaptimmune Therapeutics plc
Is this a Gift?	☐ Date Donor Acquired
Amount of Securities Acquired	29096
Date of Payment	01/15/2025
Nature of Payment	COMPENSATION

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months			
Nothing to Report			
144: Remarks and Signature			
Remarks			
Date of Notice	01/15/2025		

## **ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Adrian Rawcliffe

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)